We examined long-term protection of naturally acquired immunity, compared to vaccine-induced immunity. Group 1, N = 673,676 Vaccine not Infection Group SARS-CoV-2-naive individuals who received a 2-dose regimen of the BioNTech/Pfizer mRNA BNT162b2 vaccine. Group 2, N = 62,883 Infection not Vaccine Group Previously infected individuals who have not been vaccinated SARS-CoV-2-related outcomes June 1st to August 14th 2021 (Delta variant times) Infection, 13 times more infections in vaccinated group Symptomatic disease, 27 times more disease in vaccinated group Hospitalization, 8 in vaccinated group, 0 in infection group Death 0 / 0